On May 13, 2022, Atara Biotherapeutics, Inc. received written notice of termination from Bayer AG (“Bayer”) of the Research, Development and License Agreement dated December 4, 2020 by and between Atara and Bayer (the “License Agreement”), pursuant to which Atara granted Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by Atara and its affiliates covering or related to ATA2271 and ATA3271, the Company's next-generation CAR T immunotherapy programs targeting mesothelin (“Licensed Products”). The termination is effective as of September 13, 2022 (the “Termination Date”). In connection with the termination of the License Agreement, each of the Manufacturing and Supply Agreement, the Pharmacovigilance Agreement, the Quality Agreement and the Technology Transfer Agreement, each entered into between Atara and Bayer in March 2022, will terminate effective as of the Termination Date.